Mario Occhipinti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2019
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice	JOURNAL OF TRANSLATIONAL MEDICINE	2019
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy	ANNALS OF ONCOLOGY	2019
Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment. a case report	DRUG SAFETY - CASE REPORTS	2018
Coexistence of three EGFR mutations in an NSCLC patient: A brief report	THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS	2018
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes	ANTICANCER RESEARCH	2017
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient	ANTI-CANCER DRUGS	2017
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?	ONCOTARGET	2017
Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong	JOURNAL OF THORACIC DISEASE	2017
Degradation rate of 5-fluorouracil in metastatic colorectal cancer. A new predictive outcome biomarker?	PLOS ONE	2016
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX	ANTI-CANCER DRUGS	2016
Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: A single-center experience and review of the literature	TRANSLATIONAL LUNG CANCER RESEARCH	2016
Genetic polymorphism can help physician choosing the best lung cancer chemotherapy	ANNALS OF ONCOLOGY	2015